FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to internal diseases, and is intended for treatment cardiovascular disease treatment. Liraglutide is used to reduce the development of a major adverse cardiovascular event (MACE) in a human subject with type 2 diabetes and cardiovascular disease, which is administered in a therapeutically effective amount to a subject who needs it. The indicated MACE represents death due to cardiovascular disease, non-fatal myocardial infarction and non-fatal stroke.
EFFECT: reduces the development of MACE in a human subject with type 2 diabetes and cardiovascular disease.
13 cl, 11 tbl, 1 ex, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SEMAGLUTIDE IN CARDIOVASCULAR CONDITIONS | 2017 |
|
RU2768283C2 |
| COMPOSITIONS AND METHODS FOR REDUCING SERIOUS ADVERSE CARDIOVASCULAR EVENTS | 2014 |
|
RU2711638C2 |
| RENIN-ANGIOTENSIN SYSTEM INHIBITORS APPLICATION FOR PREVENTING CARDIOVASCULAR DISEASE MANIFESTATIONS | 2000 |
|
RU2276997C2 |
| TREATMENT OF MYOCARDIAL INFARCTION WITH REGENERATED HIGH-DENSITY LIPOPROTEIN | 2017 |
|
RU2798830C2 |
| METHODS OF TREATING PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASES HAVING HYPERCHOLESTEROLEMIA | 2015 |
|
RU2723018C2 |
| METHOD OF TREATING OR PREVENTING ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION IN PAST HISTORY | 2016 |
|
RU2707959C2 |
| GENETIC MARKERS FOR PREDICTING RESPONSE TO THERAPY BY RAISING HDL LEVEL OR IMITATING HDL AGENTS | 2015 |
|
RU2703192C2 |
| METHOD OF TREATING CHRONIC CARDIAL FAILURE | 2009 |
|
RU2512933C2 |
| CONCENTRATED THERAPEUTIC PHOSPHOLIPIDE COMPOSITIONS | 2010 |
|
RU2642653C2 |
| USE OF LEVOCETIRIZINE AND MONTELUKAST IN TREATMENT OF TRAUMATIC INJURY | 2014 |
|
RU2672871C2 |
